Related references
Note: Only part of the references are listed.Effect of dimethyl fumarate on lymphocytes in RRMS Implications for clinical practice
Devangi Mehta et al.
NEUROLOGY (2019)
Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center
Kyle Smoot et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center
Kyle Smoot et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study
Massimiliano Mirabella et al.
CNS DRUGS (2018)
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)
Stanley L. Cohan et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study
Kiren Kresa-Reahl et al.
CLINICAL THERAPEUTICS (2018)
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
Brandi Vollmer et al.
NEUROLOGY-CLINICAL PRACTICE (2018)
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS Patient management considerations
Robert J. Fox et al.
NEUROLOGY-CLINICAL PRACTICE (2016)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode
D. S. Goodin et al.
MULTIPLE SCLEROSIS (2009)
Share Paper
